# EA5181 (NCT04092283)

> Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: durvalumab
- Indication: unresectable stage III non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04092283
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma
- Interventions: Carboplatin; Cisplatin; Durvalumab; Etoposide; Paclitaxel; Pemetrexed Disodium
- Enrollment: 660
- Primary outcome: Overall survival (OS)

## Indexed commentary on EA5181 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 57 posts on X
- 3 YouTube videos
- 1 podcast episode

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ea5181-nct04092283

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04092283", "email": "<work email>"}; the inbox owner confirms by the emailed link.